Citius Pharmaceuticals, Inc. (CTXR): Price and Financial Metrics
GET POWR RATINGS... FREE!
CTXR Stock Price Chart Interactive Chart >
CTXR Price/Volume Stats
| Current price | $1.32 | 52-week high | $2.01 |
| Prev. close | $1.31 | 52-week low | $0.77 |
| Day low | $1.27 | Volume | 770,300 |
| Day high | $1.35 | Avg. volume | 1,286,278 |
| 50-day MA | $1.09 | Dividend yield | N/A |
| 200-day MA | $1.08 | Market Cap | 193.00M |
Citius Pharmaceuticals, Inc. (CTXR) Company Bio
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Latest CTXR News From Around the Web
Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity.
Investing in Citius Pharmaceuticals Inc. (CTXR) might be a great opportunity, but the stock is a bit overvaluedCitius Pharmaceuticals Inc. (NASDAQ:CTXR) marked $1.13 per share on Tuesday, up from a previous closing price of $1.12. While Citius Pharmaceuticals Inc. has overperformed by 0.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CTXR fell by -23.65%, with highs and lows ranging from $2.01 to […] |
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Could See Prices Soar In The Coming MonthsIn today’s recent session, 2.76 million shares of the Citius Pharmaceuticals Inc. (NASDAQ:CTXR) have been traded, and its beta is 1.21. Most recently the company’s share price was $1.20, and it changed around $0.07 or 6.19% from the last close, which brings the market valuation of the company to $149.02M. CTXR at last check was … Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Could See Prices Soar In The Coming Months Read More » |
Sidoti's January Micro-Cap ConferenceSidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023. |
Here's Why We're Not Too Worried About Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023. |
CTXR Price Returns
| 1-mo | 54.91% |
| 3-mo | 17.86% |
| 6-mo | 46.08% |
| 1-year | -6.38% |
| 3-year | 6.45% |
| 5-year | -69.59% |
| YTD | 67.09% |
| 2022 | -48.70% |
| 2021 | 50.98% |
| 2020 | 0.00% |
| 2019 | -1.92% |
| 2018 | -72.63% |
Loading social stream, please wait...